CSL Behring Awards Second Round of LEAD Grants in Support of Patient Group Advocacy Efforts

Five grants awarded to patient organizations for grassroots advocacy

King of Prussia, PA — 09 December 2008

CSL Behring, a global leader in the plasma-protein biotherapies industry, announces the awarding of five grants totaling more than $65,000 to patient advocacy organizations in the United States. These five grants represent the second round of semi-annual awards in the company's Local Empowerment for Advocacy Development (LEAD) program. To date, the company has awarded more than $150,000 in grants through the LEAD program.

LEAD grants support grassroots advocacy efforts by organizations committed to helping people who use plasma-derived and recombinant therapies to manage their health conditions. Grants were awarded to the following organizations in the second round:

  • Neuropathy Action Foundation
  • Hemophilia Federation of America
  • Nebraska Chapter of the National Hemophilia Foundation (NHF)
  • United Virginia Chapter of NHF
  • Delaware Valley Chapter of NHF

The grant awarded to the Neuropathy Action Foundation (NAF) will be used for the creation and distribution of a health insurance toolkit within the state of California. This toolkit will help patients with neuropathies and other rare diseases navigate the California state insurance system.

While NAF is focusing on insurance issues, the Hemophilia Federation of America is promoting advocacy. NAF has developed a Web-based advocacy toolkit called CapWiz that allows people with hemophilia to learn about legislative issues and contact their elected representatives.

"The Hemophilia Federation is delighted to be the recipient of a CSL Behring LEAD grant, which will be used to fund our online advocacy system, CapWiz," said Kimberly Haugstad, Executive Director, Hemophilia Federation of America. "This grant allows us to alert our community, families and friends of federal and state legislation and provides an easy-to-use Web-based tool designed to unify our voice and connect us with our elected officials. With most states facing budget deficits and many in Congress discussing health care system reform, timely advocacy outreach efforts are absolutely critical to our mission. We are very appreciative of CSL Behring's interest in supporting these efforts."

"As leaders in advocacy, CSL Behring continues to collaborate with patient advocacy organizations on specific initiatives to improve access to care for life-saving plasma derived and recombinant therapies," said Dennis Jackman, Senior Vice President, Public Affairs, CSL Behring. "We are committed to helping organizations expand their advocacy initiatives on both state and federal levels."

In addition to toolkits, grants were awarded to three NHF chapters for advocacy initiatives. The Nebraska Chapter will use its funding to launch Nebraska Days, day-long programs designed to teach patients, especially those residing in rural areas, how to engage in the legislative process. Similar to the Nebraska Chapter, the United Virginia Chapter is also establishing an advocacy-based program, which includes developing Webinars on advocacy for their Web site and hosting a state lobbying day in Richmond. Finally, the Delaware Valley Chapter will use their funding to advance and promote the Hemophilia Standards of Care Act within the Pennsylvania legislature.

LEAD grants are awarded biannually. The third round of grants will occur in April 2009. Applications, specific criteria for applying and more information about the LEAD program are available on the CSL Behring Web site at

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufacturers and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.

CSL Behring operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit

Media Contact:
Christine Kuhinka

LinkedIn Twitter Facebook Google+